MV Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

MV Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-39	Closed	-$7K	–	738
2021 Q2	$7K	Buy	39 +33	+550%	+$5.67K	﹤0.01%	448
2021 Q1	$1K	Buy	+6	New	+$928	﹤0.01%	460
2016 Q3	–	Sell	-26	Closed	-$3K	–	375
2016 Q2	$3K	Hold	26	–	–	﹤0.01%	309
2016 Q1	$4K	Hold	26	–	–	﹤0.01%	272
2015 Q4	$5K	Hold	26	–	–	﹤0.01%	275
2015 Q3	$4K	Hold	26	–	–	﹤0.01%	277
2015 Q2	$5K	Hold	26	–	–	﹤0.01%	360
2015 Q1	$5K	Hold	26	–	–	﹤0.01%	346
2014 Q4	$5K	Buy	+26	New	+$4.82K	﹤0.01%	391

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

MV Capital Management's ALXN Position: Q3 2021 in Review

MV Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 39 shares — an estimated $7K sold.

MV Capital Management first reported a position in ALXN in Q4 2014 and held it in 9 quarters. The position peaked at $7K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

MV Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
MV Capital Management sold 39 Alexion Pharmaceuticals shares in Q3 2021, an estimated $7K.
MV Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 9 quarters.
MV Capital Management's Alexion Pharmaceuticals position peaked at $7K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on MV Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.